All forms of hormonal contraception carry breast cancer risk, study finds
Research shows small increase in risk until about five years after contraception is stopped, despite hopes that newer types might prove saferAll forms of the pill and other hormonal contraception carry a small risk of breast cancer, which lasts for about five years after women stop taking it, according to new research.The increased risk has been known for some time, but there were hopes that newer forms of hormonal contraception – such as those which release progesterone only – would be safer. However,the new study in the New England Journal of Medicine confirms the 20% added risk that women run – although that is still very small for those not at high risk already.Continue reading...
Ken and Jane Gremling have shared everything since they got married in 1971, just three weeks after they started dating. But they never expected to receive identical breast cancer diagnoses.
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy.
Two biology researchers from Georgia State University describe the racial gap, why it eludes scientists, and what we are learning about how to close the gap.
Publication date: Available online 18 October 2018Source: Stem Cell ReportsAuthor(s): Leonor Lopez Almeida, Michael Sebbagh, François Bertucci, Pascal Finetti, Julien Wicinski, Sylvie Marchetto, Rémy Castellano, Emmanuelle Josselin, Emmanuelle Charafe-Jauffret, Christophe Ginestier, Jean-Paul Borg, Marie-Josée SantoniSummaryTumor initiation, progression, and therapeutic resistance have been proposed to originate from a subset of tumor cells, cancer stem cells (CSCs). However, the current understanding of the mechanisms involved in their self-renewal and tumor initiation capacity remains limited. Here, ...
Condition: Breast Cancer Intervention: Behavioral: Lifestyle alteration Sponsor: Hospices Civils de Lyon Recruiting
Conditions: Breast Cancer; Acute Pain; Anesthesia Interventions: Procedure: PVB group; Procedure: MTP block group; Procedure: Control Group Sponsor: Ottawa Hospital Research Institute Not yet recruiting
Condition: Breast Cancer Intervention: Drug: Caelyx® Sponsors: European Institute of Oncology; Janssen-Cilag International NV Recruiting
Condition: Breast Cancer Intervention: Device: Macrodyne LivMD plate Sponsor: Indiana University Not yet recruiting
More than 55,000 women in the UK are diagnosed with breast cancer each year, which equates to a staggering 1 in 8 women being diagnosed at some stage... The post Our Macclesfield office holds a Pink Party in aid of breast cancer appeared first on Ashfield Healthcare.
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 -- (Healthcare Sales &Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for... Biopharmaceuticals, Generics, Oncology, Regulatory Mylan, Biocon, Ogivri, Herceptin, trastuzumab, breast cancer, biosimilar